Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

Gunnar Juliusson, Professor of Hematology, who has been the Chairman of the Swedish National Acute Myeloid Leukemia Registry for about 25 years, presents in this MEDtalk data from a benchmarking study about secondary AML, which is a poor prognostic subset of acute myeloid leukemia. The study compared data from the registration study of cytarabine to the Swedish data from the national registry. It showed that the Swedish data did better – but in Sweden, they use a higher dose of cytarabine.